Zoledronic acid for congenital dyserythropoietic anemia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of congenital dyserythropoietic anemia (CDA) with a specific gene change (RBM28) or certain bone marrow cell changes.
- Your anemia must be severe enough that you have low red blood cells (hemoglobin below 10 g/dL) or need regular blood transfusions (at least every 8 weeks).
- You need to have good kidney function and normal calcium levels in your blood.
- You must not have gum disease or jaw bone damage, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects medical and lab information from people with congenital dyserythropoietic anemia (CDA), a lifelong type of anemia that can cause jaundice. It helps doctors better understand the condition and its causes, including in families where it runs.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
This trial tests whether zoledronate, a medicine that helps strengthen bones, can reduce pain in children with a rare bone condition called chronic recurrent multifocal osteomyelitis (CRMO). It compares zoledronate to a placebo (a dummy treatment) to see if it works better at easing pain after 12 weeks.
This trial tests if a bone-strengthening medicine called zoledronate can help prevent bone problems in children and teens who have had a stem cell transplant. It may be an option for patients with low bone density or those who develop graft-versus-host disease after transplant.
Hear when a new Congenital Dyserythropoietic Anemia (CDA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.